VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q59558816  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241221010729.0
008     241221nneanz||abbn n and d
035 ‎‡a  (WKP)Q59558816‏
024 ‎‡a  0000-0001-7801-5374‏ ‎‡2  orcid‏
024 ‎‡a  35444694300‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q59558816‏
100 0 ‎‡a  Julio A Ramirez‏ ‎‡c  researcher ORCID ID = 0000-0001-7801-5374‏ ‎‡9  en‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  Julio A Ramirez‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's A process for analysis of sentinel events due to health care-associated infection‏
670 ‎‡a  Author's A Randomized Study Evaluating the Effectiveness of Oseltamivir Initiated at the Time of Hospital Admission in Adults Hospitalized With Influenza-Associated Lower Respiratory Tract Infections.‏
670 ‎‡a  Author's A single genotype of Acinetobacter baumannii expresses multiple antibiotic susceptibility phenotypes‏
670 ‎‡a  Author's A worldwide perspective of atypical pathogens in community-acquired pneumonia.‏
670 ‎‡a  Author's A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia.‏
670 ‎‡a  Author's Absence of gender-based differences in outcome of patients with hospital-acquired pneumonia‏
670 ‎‡a  Author's Acute myocardial infarction in hospitalized patients with community-acquired pneumonia‏
670 ‎‡a  Author's Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia‏
670 ‎‡a  Author's Addressing the challenges of refugee health: Experiences from the University of Louisville interprofessional refugee immunization clinic‏
670 ‎‡a  Author's Adherence with national guidelines in hospitalized patients with community-acquired pneumonia: results from the CAPO study in Venezuela‏
670 ‎‡a  Author's Adults Hospitalized with Pneumonia in the United States: Incidence, Epidemiology & Mortality‏
670 ‎‡a  Author's Adults Hospitalized with Pneumonia in the United States: Incidence, Epidemiology and Mortality‏
670 ‎‡a  Author's Advances in antibiotic use: Switch therapy‏
670 ‎‡a  Author's Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus‏
670 ‎‡a  Author's Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009‏
670 ‎‡a  Author's Antibiotic streamlining: development and justification of an antibiotic streamlining program‏
670 ‎‡a  Author's Antigens of persistent Chlamydia pneumoniae within coronary atheroma from patients undergoing heart transplantation‏
670 ‎‡a  Author's Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia‏
670 ‎‡a  Author's Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response.‏
670 ‎‡a  Author's Cardiac diseases complicating community-acquired pneumonia‏
670 ‎‡a  Author's CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients‏
670 ‎‡a  Author's Changing needs of community-acquired pneumonia‏
670 ‎‡a  Author's Characteristics associated with clinician diagnosis of aspiration pneumonia: a descriptive study of afflicted patients and their outcomes‏
670 ‎‡a  Author's Characteristics of hospitalised patients with 2009 H1N1 influenza in Chile.‏
670 ‎‡a  Author's Characterization of Chlamydia pneumoniae persistence in HEp-2 cells treated with gamma interferon.‏
670 ‎‡a  Author's Clinical and economic burden of pneumonia among adults in Latin America‏
670 ‎‡a  Author's Clinical outcomes of HIV-infected patients hospitalized with bacterial community-acquired pneumonia.‏
670 ‎‡a  Author's Clinical scoring tools: which is best to predict clinical response and long-term outcomes?‏
670 ‎‡a  Author's Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet?‏
670 ‎‡a  Author's Collaboration with clinical and translational sciences to improve psychiatry training in research‏
670 ‎‡a  Author's Combination antibiotic therapy and synergy in HAP and VAP‏
670 ‎‡a  Author's Community-acquired pneumonia in adults‏
670 ‎‡a  Author's Community-Acquired Pneumonia in the Elderly Reply‏
670 ‎‡a  Author's Comparative study of the bactericidal activity of ampicillin/sulbactam and erythromycin against intracellular Legionella pneumophila.‏
670 ‎‡a  Author's Comparing posteroanterior with lateral and anteroposterior chest radiography in the initial detection of parapneumonic effusions.‏
670 ‎‡a  Author's Computed tomography measurements of parapneumonic effusion indicative of thoracentesis.‏
670 ‎‡a  Author's Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia‏
670 ‎‡a  Author's Controlling multiple-drug-resistant organisms at the hospital level‏
670 ‎‡a  Author's Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia‏
670 ‎‡a  Author's Criteria for clinical stability in hospitalised patients with community-acquired pneumonia‏
670 ‎‡a  Author's Cytokines and neutrophils responses in influenza pneumonia.‏
670 ‎‡a  Author's De-escalation therapy among bacteraemic patients with community-acquired pneumonia.‏
670 ‎‡a  Author's Decrease in long-term survival for hospitalized patients with community-acquired pneumonia‏
670 ‎‡a  Author's Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study‏
670 ‎‡a  Author's Diagnostic sensitivity and specificity of the radionuclide (indium)-labeled leukocyte scan‏
670 ‎‡a  Author's Disinfectant sprays versus wipes: Applications in behavioral health‏
670 ‎‡a  Author's Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia.‏
670 ‎‡a  Author's Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes‏
670 ‎‡a  Author's Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice‏
670 ‎‡a  Author's Early Switch From Intravenous to Oral Antibiotics and Early Hospital Discharge‏
670 ‎‡a  Author's Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha‏
670 ‎‡a  Author's Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.‏
670 ‎‡a  Author's Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells‏
670 ‎‡a  Author's Efficacy of a novel skin antiseptic against carbapenem-resistant Enterobacteriaceae‏
670 ‎‡a  Author's Emergence of methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of late-onset nosocomial pneumonia in intensive care patients in the USA.‏
670 ‎‡a  Author's Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia.‏
670 ‎‡a  Author's Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis.‏
670 ‎‡a  Author's Establishing a hospital program to improve antimicrobial use, control bacterial resistance and contain healthcare costs: the University of Louisville experience.‏
670 ‎‡a  Author's Evaluating Mental Health in Cuban Refugees: The Role of the Refugee Health Screener-15‏
670 ‎‡a  Author's Evaluation of the effectiveness of improved hydrogen peroxide in the operating room‏
670 ‎‡a  Author's Evaluation of the knowledge-sharing social network of hospital-based infection preventionists in Kentucky‏
670 ‎‡a  Author's Evidence for persistent Chlamydia pneumoniae infection of human coronary atheromas‏
670 ‎‡a  Author's Future research directions in pneumonia: NHLBI working group report‏
670 ‎‡a  Author's Global changes in the epidemiology of community-acquired pneumonia‏
670 ‎‡a  Author's Googling your hand hygiene data: Using Google Forms, Google Sheets, and R to collect and automate analysis of hand hygiene compliance monitoring‏
670 ‎‡a  Author's Guidelines for community-acquired pneumonia in the US and Canada: a practical approach to antibiotic selection‏
670 ‎‡a  Author's Guidelines for Community-Acquired Pneumonia Within Disease Management Programs‏
670 ‎‡a  Author's Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia‏
670 ‎‡a  Author's Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention‏
670 ‎‡a  Author's Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study‏
670 ‎‡a  Author's HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study.‏
670 ‎‡a  Author's HIV-Negative “AIDS” in Kentucky: A Case of Idiopathic CD4+ Lymphopenia and Cryptococcal Meningitis‏
670 ‎‡a  Author's Hospitalization due to community-acquired pneumonia in patients with chronic obstructive pulmonary disease: incidence, epidemiology and outcomes‏
670 ‎‡a  Author's Hospitalization for Community-Acquired Pneumonia‏
670 ‎‡a  Author's How can we improve clinical research in pneumonia?‏
670 ‎‡a  Author's How to choose the duration of antibiotic therapy in patients with pneumonia‏
670 ‎‡a  Author's How to handle mortality when investigating length of hospital stay and time to clinical stability‏
670 ‎‡a  Author's Impact of age and gender on efficacy and safety of omadacycline‏
670 ‎‡a  Author's Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP)‏
670 ‎‡a  Author's Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study‏
670 ‎‡a  Author's Improving antimicrobial use in the hospital setting by providing usage feedback to prescribing physicians‏
670 ‎‡a  Author's Improving Antimicrobial Use: Longitudinal Assessment of an Antimicrobial Team Including a Clinical Pharmacist‏
670 ‎‡a  Author's Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.‏
670 ‎‡a  Author's Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia‏
670 ‎‡a  Author's Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.‏
670 ‎‡a  Author's Individualizing duration of antibiotic therapy in community-acquired pneumonia‏
670 ‎‡a  Author's Infection prevention and control and the refugee population: Experiences from the University of Louisville Global Health Center‏
670 ‎‡a  Author's Influenza and Viral Pneumonia‏
670 ‎‡a  Author's Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha.‏
670 ‎‡a  Author's Inhibition of Chlamydia pneumoniae replication in HEp-2 cells by interferon-gamma: role of tryptophan catabolism.‏
670 ‎‡a  Author's Inhibition of oxidative burst and chemotaxis in human phagocytes by Legionella pneumophila zinc metalloprotease.‏
670 ‎‡a  Author's Introduction‏
670 ‎‡a  Author's Kawasaki-like disease‏
670 ‎‡a  Author's Kawasaki-like disease (KLD) in an adult with congenital HIV infection‏
670 ‎‡a  Author's Knowledge sharing among healthcare infection preventionists: the impact of public health professionals in a rural state‏
670 ‎‡a  Author's Legionnaires Disease and the Updated IDSA Guidelines for Community‐Acquired Pneumonia‏
670 ‎‡a  Author's Level of Recall Bias Regarding Pneumococcal Vaccination History among Adults Hospitalized with Community-Acquired Pneumonia: Results from the University of Louisville Pneumonia Study‏
670 ‎‡a  Author's Long-term Mortality in Hospitalized Patients With Community-Acquired Pneumonia‏
670 ‎‡a  Author's Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia‏
670 ‎‡a  Author's Lung Cytokines and Systemic Inflammation in Patients with COPD‏
670 ‎‡a  Author's Macrolide Use and Neutrophil Function/Cytokine Levels in Hospitalized Patients with Community-Acquired Pneumonia: A Pilot Study‏
670 ‎‡a  Author's Methicillin-resistant Staphylococcus aureus resistance to non-beta-lactam antimicrobials in the United States from 1996 to 2008.‏
670 ‎‡a  Author's Methods for computational disease surveillance in infection prevention and control: Statistical process control versus Twitter's anomaly and breakout detection algorithms‏
670 ‎‡a  Author's Microbiological efficacy of ABT-773‏
670 ‎‡a  Author's Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae‏
670 ‎‡a  Author's Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review‏
670 ‎‡a  Author's Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization‏
670 ‎‡a  Author's Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study‏
670 ‎‡a  Author's Multicenter, multinational observational studies: a new approach to studying community-acquired pneumonia‏
670 ‎‡a  Author's Neutrophil function in elderly patients hospitalized with community-acquired pneumonia‏
670 ‎‡a  Author's Nontuberculous mycobacterial pulmonary infections‏
670 ‎‡a  Author's One-Year Mortality in Patients with Community-Acquired Pneumonia‏
670 ‎‡a  Author's Opioid overdose leading to intensive care unit admission: Epidemiology and outcomes‏
670 ‎‡a  Author's Outcomes in females hospitalised with community-acquired pneumonia are worse than in males‏
670 ‎‡a  Author's Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit‏
670 ‎‡a  Author's Phenotypic differences in virulence and immune response in closely related clinical isolates of influenza A 2009 H1N1 pandemic viruses in mice‏
670 ‎‡a  Author's Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis‏
670 ‎‡a  Author's Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia‏
670 ‎‡a  Author's Pneumonia and Mortality Beyond Hospital Discharge in Elderly Patients: Response‏
670 ‎‡a  Author's Pneumonia Pathogenesis and the Lung Microbiome: Back to the Drawing Board‏
670 ‎‡a  Author's Possible role of tetracyclines on decreasing the accelerated aging process of well-controlled HIV patients on antiretroviral therapy‏
670 ‎‡a  Author's PREDICTING ADMISSION TO THE ICU IN COMMUNITY-ACQUIRED PNEUMONIA‏
670 ‎‡a  Author's Predicting mortality in patients with ventilator-associated pneumonia: The APACHE II score versus the new IBMP-10 score‏
670 ‎‡a  Author's Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia‏
670 ‎‡a  Author's Predicting the need for ICU admission in community-acquired pneumonia‏
670 ‎‡a  Author's Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization‏
670 ‎‡a  Author's Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study‏
670 ‎‡a  Author's Process control charts in infection prevention: Make it simple to make it happen‏
670 ‎‡a  Author's Processes of care for community-acquired pneumonia‏
670 ‎‡a  Author's Proteomic analysis of differentially expressed Chlamydia pneumoniae genes during persistent infection of HEp-2 cells‏
670 ‎‡a  Author's Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia‏
670 ‎‡a  Author's Real-Time Enrollment Dashboard For Multisite Clinical Trials.‏
670 ‎‡a  Author's Recruitment manoeuvres dislodge mucus towards the distal airways in an experimental model of severe pneumonia‏
670 ‎‡a  Author's Reduction in tuberculin skin-test conversion rate after improved adherence to tuberculosis isolation‏
670 ‎‡a  Author's Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia‏
670 ‎‡a  Author's Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells‏
670 ‎‡a  Author's Research Needs on Respiratory Health in Migrant and Refugee Populations. An Official American Thoracic Society and European Respiratory Society Workshop Report‏
670 ‎‡a  Author's Risk factors for pulmonary tuberculosis in community-acquired pneumonia‏
670 ‎‡a  Author's Role of Atypical Pathogens in the Etiology of Community-Acquired Pneumonia‏
670 ‎‡a  Author's RSV infection in the adult population.‏
670 ‎‡a  Author's Ruling out Legionella in community-acquired pneumonia‏
670 ‎‡a  Author's Septicemia in patients with AIDS admitted to a university health system: a case series of eighty-three patients‏
670 ‎‡a  Author's Severity of Disease and Clinical Outcomes in Patients With Hospital-Acquired Pneumonia Due to Methicillin-Resistant Staphylococcus aureus Strains Not Influenced by the Presence of the Panton-Valentine Leukocidin Gene‏
670 ‎‡a  Author's SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia‏
670 ‎‡a  Author's Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia‏
670 ‎‡a  Author's Switch Therapy in Adult Patients with Pneumonia‏
670 ‎‡a  Author's Switch therapy in community-acquried pneumonia‏
670 ‎‡a  Author's Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin‏
670 ‎‡a  Author's Switch Therapy with β-Lactam/β-Lactamase Inhibitors in Patients with Community-Acquired Pneumonia‏
670 ‎‡a  Author's TB Test Results May Be Skewed‏
670 ‎‡a  Author's Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections‏
670 ‎‡a  Author's The author replies‏
670 ‎‡a  Author's The Challenge of Predicting Influenza‏
670 ‎‡a  Author's The choice of empirical antibiotic therapy for nosocomial pneumonia.‏
670 ‎‡a  Author's The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: Results from the Community-Acquired Pneumonia O‏
670 ‎‡a  Author's The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia‏
670 ‎‡a  Author's The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization‏
670 ‎‡a  Author's The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization‏
670 ‎‡a  Author's The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study‏
670 ‎‡a  Author's The role of infection prevention conferences to build and maintain knowledge-sharing networks: a longitudinal evaluation‏
670 ‎‡a  Author's The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia‏
670 ‎‡a  Author's The upper respiratory tract microbiome of hospitalised patients with community-acquired pneumonia of unknown aetiology: a pilot study‏
670 ‎‡a  Author's The use of heteroduplex analysis of polymerase chain reaction products to support the possible transmission of Legionella pneumophila from a malfunctioning automobile air conditioner‏
670 ‎‡a  Author's The use of large databases to study pneumonia: what is their value?‏
670 ‎‡a  Author's The value of ready-to-use disinfectant wipes: compliance, employee time, and costs‏
670 ‎‡a  Author's Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia‏
670 ‎‡a  Author's Thrombocytosis in Patients With Severe Community-Acquired Pneumonia: Response‏
670 ‎‡a  Author's Tissue MicroArray (TMA) analysis of normal and persistent Chlamydophila pneumoniae infection‏
670 ‎‡a  Author's Treatment of hospital-acquired pneumonia – Authors' Reply‏
670 ‎‡a  Author's Tuberculosis is always a possibility (even in the intensive care unit).‏
670 ‎‡a  Author's Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia‏
670 ‎‡a  Author's Understanding why low-risk patients accept vaccines: a socio-behavioral approach‏
670 ‎‡a  Author's Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study‏
670 ‎‡a  Author's Using Steroids in Patients with Community-Acquired Pneumonia at the University of Louisville Hospital: Who, What, and When‏
670 ‎‡a  Author's Ventilator-associated pneumonia in critically ill stroke patients: Frequency, risk factors, and outcomes‏
670 ‎‡a  Author's Viral infection in community-acquired pneumonia: a systematic review and meta-analysis‏
670 ‎‡a  Author's Visual grids for managing data completeness in clinical research datasets‏
670 ‎‡a  Author's Vitamin D receptor homozygote mutant tt and bb are associated with susceptibility to pulmonary tuberculosis in the Iranian population.‏
670 ‎‡a  Author's What is the association of cardiovascular events with clinical failure in patients with community-acquired pneumonia?‏
670 ‎‡a  Author's What is the best therapeutic approach to methicillin-resistant Staphylococcus aureus pneumonia?‏
670 ‎‡a  Author's Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study‏
670 ‎‡a  Author's شروع به کار با داده های بهداشتی دست شما: با استفاده از فرم های Google ، Google Sheets و R برای جمع آوری و خودکار کردن تجزیه و تحلیل نظارت بر رعایت بهداشت دست.‏
670 ‎‡a  Author's ভূমিকা‏
670 ‎‡a  wikidata authority control‏ ‎‡u  https://viaf.org/viaf/43668106‏
670 ‎‡a  wikidata authority control‏ ‎‡u  https://viaf.org/processed/LC|n 2002136142‏
909 ‎‡a  (scopus) 35444694300‏ ‎‡9  1‏
909 ‎‡a  (orcid) 0000000178015374‏ ‎‡9  1‏
912 ‎‡a  introduction‏ ‎‡A  Introduction‏ ‎‡9  1‏
912 ‎‡a  ভমক‏ ‎‡A  ভূমিকা‏ ‎‡9  1‏
919 ‎‡a  lowcurb65isoflimitedvalueindecidingdischargeofpatientswithcommunityacquiredpneumonia‏ ‎‡A  Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  methicillinresistantstaphylococcusaureusresistancetononbetalactamantimicrobialsintheunitedstatesfrom1996to‏ ‎‡A  Methicillin-resistant Staphylococcus aureus resistance to non-beta-lactam antimicrobials in the United States from 1996 to 2008.‏ ‎‡9  1‏
919 ‎‡a  longtermmortalityinhospitalizedpatientswithcommunityacquiredpneumonia‏ ‎‡A  Long-term Mortality in Hospitalized Patients With Community-Acquired Pneumonia‏ ‎‡9  1‏
919 ‎‡a  levelofrecallbiasregardingpneumococcalvaccinationhistoryamongadultshospitalizedwithcommunityacquiredpneumoniaresultsfromtheuniversityoflouisvillepneumoniastudy‏ ‎‡A  Level of Recall Bias Regarding Pneumococcal Vaccination History among Adults Hospitalized with Community-Acquired Pneumonia: Results from the University of Louisville Pneumonia Study‏ ‎‡9  1‏
919 ‎‡a  methodsforcomputationaldiseasesurveillanceininfectionpreventionandcontrolstatisticalprocesscontrolversustwittersanomalyandbreakoutdetectionalgorithms‏ ‎‡A  Methods for computational disease surveillance in infection prevention and control: Statistical process control versus Twitter's anomaly and breakout detection algorithms‏ ‎‡9  1‏
919 ‎‡a  legionnairesdiseaseandtheupdatedidsaguidelinesforcommunityacquiredpneumonia‏ ‎‡A  Legionnaires Disease and the Updated IDSA Guidelines for Community‐Acquired Pneumonia‏ ‎‡9  1‏
919 ‎‡a  microbiologicalefficacyofabt773‏ ‎‡A  Microbiological efficacy of ABT-773‏ ‎‡9  1‏
919 ‎‡a  knowledgesharingamonghealthcareinfectionpreventioniststheimpactofpublichealthprofessionalsinaruralstate‏ ‎‡A  Knowledge sharing among healthcare infection preventionists: the impact of public health professionals in a rural state‏ ‎‡9  1‏
919 ‎‡a  microbiologicalefficacyofabt773cethromycinforthetreatmentofcommunityacquiredpneumoniaduetochlamydiapneumoniae‏ ‎‡A  Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae‏ ‎‡9  1‏
919 ‎‡a  kawasakilikediseasekldinanadultwithcongenitalhivinfection‏ ‎‡A  Kawasaki-like disease (KLD) in an adult with congenital HIV infection‏ ‎‡9  1‏
919 ‎‡a  midregionalproadrenomedullinforprognosisincommunityacquiredpneumoniaasystematicreview‏ ‎‡A  Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review‏ ‎‡9  1‏
919 ‎‡a  kawasakilikedisease‏ ‎‡A  Kawasaki-like disease‏ ‎‡9  1‏
919 ‎‡a  mortalitydifferencesamonghospitalizedpatientswithcommunityacquiredpneumoniain3worldregionsresultsfromthecommunityacquiredpneumoniaorganization‏ ‎‡A  Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization‏ ‎‡9  1‏
919 ‎‡a  mortalitydifferencesamonghospitalizedpatientswithcommunityacquiredpneumoniain3worldregionsresultsfromthecommunityacquiredpneumoniaorganizationcapointernationalcohortstudy‏ ‎‡A  Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study‏ ‎‡9  1‏
919 ‎‡a  multicentermultinationalobservationalstudiesanewapproachtostudyingcommunityacquiredpneumonia‏ ‎‡A  Multicenter, multinational observational studies: a new approach to studying community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  neutrophilfunctioninelderlypatientshospitalizedwithcommunityacquiredpneumonia‏ ‎‡A  Neutrophil function in elderly patients hospitalized with community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  nontuberculousmycobacterialpulmonaryinfections‏ ‎‡A  Nontuberculous mycobacterial pulmonary infections‏ ‎‡9  1‏
919 ‎‡a  1yearmortalityinpatientswithcommunityacquiredpneumonia‏ ‎‡A  One-Year Mortality in Patients with Community-Acquired Pneumonia‏ ‎‡9  1‏
919 ‎‡a  opioidoverdoseleadingtointensivecareunitadmissionepidemiologyandoutcomes‏ ‎‡A  Opioid overdose leading to intensive care unit admission: Epidemiology and outcomes‏ ‎‡9  1‏
919 ‎‡a  inhibitionofoxidativeburstandchemotaxisinhumanphagocytesbylegionellapneumophilazincmetalloprotease‏ ‎‡A  Inhibition of oxidative burst and chemotaxis in human phagocytes by Legionella pneumophila zinc metalloprotease.‏ ‎‡9  1‏
919 ‎‡a  inhibitionofchlamydiapneumoniaereplicationinhep2cellsbyinterferongammaroleoftryptophancatabolism‏ ‎‡A  Inhibition of Chlamydia pneumoniae replication in HEp-2 cells by interferon-gamma: role of tryptophan catabolism.‏ ‎‡9  1‏
919 ‎‡a  outcomesinfemaleshospitalisedwithcommunityacquiredpneumoniaareworsethaninmales‏ ‎‡A  Outcomes in females hospitalised with community-acquired pneumonia are worse than in males‏ ‎‡9  1‏
919 ‎‡a  outcomesinpatientswithcommunityacquiredpneumoniaadmittedtotheintensivecareunit‏ ‎‡A  Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit‏ ‎‡9  1‏
919 ‎‡a  phenotypicdifferencesinvirulenceandimmuneresponseincloselyrelatedclinicalisolatesofinfluenzaa2009h1n1pandemicvirusesinmice‏ ‎‡A  Phenotypic differences in virulence and immune response in closely related clinical isolates of influenza A 2009 H1N1 pandemic viruses in mice‏ ‎‡9  1‏
919 ‎‡a  phenotypingcommunityacquiredpneumoniaaccordingtothepresenceofacuterespiratoryfailureandseveresepsis‏ ‎‡A  Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis‏ ‎‡9  1‏
919 ‎‡a  pneumococcalepidemiologyamongusadultshospitalizedforcommunityacquiredpneumonia‏ ‎‡A  Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  pneumoniaandmortalitybeyondhospitaldischargeinelderlypatientsresponse‏ ‎‡A  Pneumonia and Mortality Beyond Hospital Discharge in Elderly Patients: Response‏ ‎‡9  1‏
919 ‎‡a  pneumoniapathogenesisandthelungmicrobiomebacktothedrawingboard‏ ‎‡A  Pneumonia Pathogenesis and the Lung Microbiome: Back to the Drawing Board‏ ‎‡9  1‏
919 ‎‡a  possibleroleoftetracyclinesondecreasingtheacceleratedagingprocessofwellcontrolledhivpatientsonantiretroviraltherapy‏ ‎‡A  Possible role of tetracyclines on decreasing the accelerated aging process of well-controlled HIV patients on antiretroviral therapy‏ ‎‡9  1‏
919 ‎‡a  predictingadmissiontotheicuincommunityacquiredpneumonia‏ ‎‡A  PREDICTING ADMISSION TO THE ICU IN COMMUNITY-ACQUIRED PNEUMONIA‏ ‎‡9  1‏
919 ‎‡a  predictingmortalityinpatientswithventilatorassociatedpneumoniatheapache2scoreversusthenewibmp10score‏ ‎‡A  Predicting mortality in patients with ventilator-associated pneumonia: The APACHE II score versus the new IBMP-10 score‏ ‎‡9  1‏
919 ‎‡a  predictingmycobacteriumtuberculosisinpatientswithcommunityacquiredpneumonia‏ ‎‡A  Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  predictingtheneedforicuadmissionincommunityacquiredpneumonia‏ ‎‡A  Predicting the need for ICU admission in community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  predictiveaccuracyofthepneumoniaseverityindexvscrb65fortimetoclinicalstabilityresultsfromthecommunityacquiredpneumoniaorganization‏ ‎‡A  Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization‏ ‎‡9  1‏
919 ‎‡a  predictiveaccuracyofthepneumoniaseverityindexvscrb65fortimetoclinicalstabilityresultsfromthecommunityacquiredpneumoniaorganizationcapointernationalcohortstudy‏ ‎‡A  Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study‏ ‎‡9  1‏
919 ‎‡a  processcontrolchartsininfectionpreventionmakeitsimpletomakeithappen‏ ‎‡A  Process control charts in infection prevention: Make it simple to make it happen‏ ‎‡9  1‏
919 ‎‡a  processesofcareforcommunityacquiredpneumonia‏ ‎‡A  Processes of care for community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  proteomicanalysisofdifferentiallyexpressedchlamydiapneumoniaegenesduringpersistentinfectionofhep2cells‏ ‎‡A  Proteomic analysis of differentially expressed Chlamydia pneumoniae genes during persistent infection of HEp-2 cells‏ ‎‡9  1‏
919 ‎‡a  randomizedphase2trialtoevaluatetheclinicalefficacyof2highdosagetigecyclineregimensversusimipenemcilastatinfortreatmentofhospitalacquiredpneumonia‏ ‎‡A  Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  realtimeenrollmentdashboardformultisiteclinicaltrials‏ ‎‡A  Real-Time Enrollment Dashboard For Multisite Clinical Trials.‏ ‎‡9  1‏
919 ‎‡a  inhibitionofchlamydiapneumoniaegrowthinhep2cellspretreatedwithgammainterferonandtumornecrosisfactoralpha‏ ‎‡A  Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha.‏ ‎‡9  1‏
919 ‎‡a  recruitmentmanoeuvresdislodgemucustowardsthedistalairwaysinanexperimentalmodelofseverepneumonia‏ ‎‡A  Recruitment manoeuvres dislodge mucus towards the distal airways in an experimental model of severe pneumonia‏ ‎‡9  1‏
919 ‎‡a  influenzaandviralpneumonia‏ ‎‡A  Influenza and Viral Pneumonia‏ ‎‡9  1‏
919 ‎‡a  reductionintuberculinskintestconversionrateafterimprovedadherencetotuberculosisisolation‏ ‎‡A  Reduction in tuberculin skin-test conversion rate after improved adherence to tuberculosis isolation‏ ‎‡9  1‏
919 ‎‡a  relationshipofvancomycinminimuminhibitoryconcentrationtomortalityinpatientswithmethicillinresistantstaphylococcusaureushospitalacquiredventilatorassociatedorhealthcareassociatedpneumonia‏ ‎‡A  Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia‏ ‎‡9  1‏
919 ‎‡a  replicationofchlamydiapneumoniaeinvitroinhumanmacrophagesendothelialcellsandaorticarterysmoothmusclecells‏ ‎‡A  Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells‏ ‎‡9  1‏
919 ‎‡a  infectionpreventionandcontrolandtherefugeepopulationexperiencesfromtheuniversityoflouisvilleglobalhealthcenter‏ ‎‡A  Infection prevention and control and the refugee population: Experiences from the University of Louisville Global Health Center‏ ‎‡9  1‏
919 ‎‡a  researchneedsonrespiratoryhealthinmigrantandrefugeepopulationsanofficialamericanthoracicsocietyandeuropeanrespiratorysocietyworkshopreport‏ ‎‡A  Research Needs on Respiratory Health in Migrant and Refugee Populations. An Official American Thoracic Society and European Respiratory Society Workshop Report‏ ‎‡9  1‏
919 ‎‡a  individualizingdurationofantibiotictherapyincommunityacquiredpneumonia‏ ‎‡A  Individualizing duration of antibiotic therapy in community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  riskfactorsforpulmonarytuberculosisincommunityacquiredpneumonia‏ ‎‡A  Risk factors for pulmonary tuberculosis in community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  roleofatypicalpathogensintheetiologyofcommunityacquiredpneumonia‏ ‎‡A  Role of Atypical Pathogens in the Etiology of Community-Acquired Pneumonia‏ ‎‡9  1‏
919 ‎‡a  rsvinfectionintheadultpopulation‏ ‎‡A  RSV infection in the adult population.‏ ‎‡9  1‏
919 ‎‡a  rulingoutlegionellaincommunityacquiredpneumonia‏ ‎‡A  Ruling out Legionella in community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  septicemiainpatientswithaidsadmittedtoauniversityhealthsystemacaseseriesofeighty3patients‏ ‎‡A  Septicemia in patients with AIDS admitted to a university health system: a case series of eighty-three patients‏ ‎‡9  1‏
919 ‎‡a  severityofdiseaseandclinicaloutcomesinpatientswithhospitalacquiredpneumoniaduetomethicillinresistantstaphylococcusaureusstrainsnotinfluencedbythepresenceofthepantonvalentineleukocidingene‏ ‎‡A  Severity of Disease and Clinical Outcomes in Patients With Hospital-Acquired Pneumonia Due to Methicillin-Resistant Staphylococcus aureus Strains Not Influenced by the Presence of the Panton-Valentine Leukocidin Gene‏ ‎‡9  1‏
919 ‎‡a  smartcopatoolforpredictingtheneedforintensiverespiratoryorvasopressorsupportincommunityacquiredpneumonia‏ ‎‡A  SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  sparfloxacinversusclarithromycininthetreatmentofcommunityacquiredpneumonia‏ ‎‡A  Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  switchtherapyinadultpatientswithpneumonia‏ ‎‡A  Switch Therapy in Adult Patients with Pneumonia‏ ‎‡9  1‏
919 ‎‡a  switchtherapyincommunityacquriedpneumonia‏ ‎‡A  Switch therapy in community-acquried pneumonia‏ ‎‡9  1‏
919 ‎‡a  switchtherapyinhospitalizedpatientswithcommunityacquiredpneumoniatigecyclinevslevofloxacin‏ ‎‡A  Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin‏ ‎‡9  1‏
919 ‎‡a  switchtherapywithβlactamβlactamaseinhibitorsinpatientswithcommunityacquiredpneumonia‏ ‎‡A  Switch Therapy with β-Lactam/β-Lactamase Inhibitors in Patients with Community-Acquired Pneumonia‏ ‎‡9  1‏
919 ‎‡a  tbtestresultsmaybeskewed‏ ‎‡A  TB Test Results May Be Skewed‏ ‎‡9  1‏
919 ‎‡a  telavancinforthetreatmentofmethicillinresistantstaphylococcusaureusboneandjointinfections‏ ‎‡A  Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections‏ ‎‡9  1‏
919 ‎‡a  authorreplies‏ ‎‡A  The author replies‏ ‎‡9  1‏
919 ‎‡a  incidenceofnephrotoxicityandassociationwithvancomycinuseinintensivecareunitpatientswithpneumoniaretrospectiveanalysisoftheimpacthapdatabase‏ ‎‡A  Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.‏ ‎‡9  1‏
919 ‎‡a  incidenceetiologytimingandriskfactorsforclinicalfailureinhospitalizedpatientswithcommunityacquiredpneumonia‏ ‎‡A  Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  challengeofpredictinginfluenza‏ ‎‡A  The Challenge of Predicting Influenza‏ ‎‡9  1‏
919 ‎‡a  improvingantimicrobialuselongitudinalassessmentofanantimicrobialteamincludingaclinicalpharmacist‏ ‎‡A  Improving Antimicrobial Use: Longitudinal Assessment of an Antimicrobial Team Including a Clinical Pharmacist‏ ‎‡9  1‏
919 ‎‡a  improvingantimicrobialuseinthehospitalsettingbyprovidingusagefeedbacktoprescribingphysicians‏ ‎‡A  Improving antimicrobial use in the hospital setting by providing usage feedback to prescribing physicians‏ ‎‡9  1‏
919 ‎‡a  implementationofguidelinesformanagementofpossiblemultidrugresistantpneumoniainintensivecareanobservationalmulticentrecohortstudy‏ ‎‡A  Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study‏ ‎‡9  1‏
919 ‎‡a  impactofageandgenderonefficacyandsafetyofomadacyclineomcvsmoxifloxacinmoxincommunityacquiredbacterialpneumoniacabp‏ ‎‡A  Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP)‏ ‎‡9  1‏
919 ‎‡a  impactofageandgenderonefficacyandsafetyofomadacycline‏ ‎‡A  Impact of age and gender on efficacy and safety of omadacycline‏ ‎‡9  1‏
919 ‎‡a  howtohandlemortalitywheninvestigatinglengthofhospitalstayandtimetoclinicalstability‏ ‎‡A  How to handle mortality when investigating length of hospital stay and time to clinical stability‏ ‎‡9  1‏
919 ‎‡a  howtochoosethedurationofantibiotictherapyinpatientswithpneumonia‏ ‎‡A  How to choose the duration of antibiotic therapy in patients with pneumonia‏ ‎‡9  1‏
919 ‎‡a  howcanweimproveclinicalresearchinpneumonia‏ ‎‡A  How can we improve clinical research in pneumonia?‏ ‎‡9  1‏
919 ‎‡a  hospitalizationforcommunityacquiredpneumonia‏ ‎‡A  Hospitalization for Community-Acquired Pneumonia‏ ‎‡9  1‏
919 ‎‡a  hospitalizationduetocommunityacquiredpneumoniainpatientswithchronicobstructivepulmonarydiseaseincidenceepidemiologyandoutcomes‏ ‎‡A  Hospitalization due to community-acquired pneumonia in patients with chronic obstructive pulmonary disease: incidence, epidemiology and outcomes‏ ‎‡9  1‏
919 ‎‡a  hivnegativeaidsinkentuckyacaseofidiopathiccd4+lymphopeniaandcryptococcalmeningitis‏ ‎‡A  HIV-Negative “AIDS” in Kentucky: A Case of Idiopathic CD4+ Lymphopenia and Cryptococcal Meningitis‏ ‎‡9  1‏
919 ‎‡a  choiceofempiricalantibiotictherapyfornosocomialpneumonia‏ ‎‡A  The choice of empirical antibiotic therapy for nosocomial pneumonia.‏ ‎‡9  1‏
919 ‎‡a  effectivenessofthepolysaccharidepneumococcalvaccineforthepreventionofhospitalizationsduetostreptococcuspneumoniaecommunityacquiredpneumoniaintheelderlydiffersbetweenthesexesresultsfromthecommunityacquiredpneumoniao‏ ‎‡A  The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: Results from the Community-Acquired Pneumonia O‏ ‎‡9  1‏
919 ‎‡a  impactofageandcomorbiditiesonthemortalityofpatientsofdifferentagegroupsadmittedwithcommunityacquiredpneumonia‏ ‎‡A  The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia‏ ‎‡9  1‏
919 ‎‡a  orderofadministrationofmacrolidesandbetalactamsmayimpacttheoutcomesofhospitalizedpatientswithcommunityacquiredpneumoniaresultsfromthecommunityacquiredpneumoniaorganization‏ ‎‡A  The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization‏ ‎‡9  1‏
919 ‎‡a  presenceofpneumococcalbacteremiadoesnotinfluenceclinicaloutcomesinpatientswithcommunityacquiredpneumoniaresultsfromthecommunityacquiredpneumoniaorganization‏ ‎‡A  The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization‏ ‎‡9  1‏
919 ‎‡a  presenceofpneumococcalbacteremiadoesnotinfluenceclinicaloutcomesinpatientswithcommunityacquiredpneumoniaresultsfromthecommunityacquiredpneumoniaorganizationcapointernationalcohortstudy‏ ‎‡A  The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study‏ ‎‡9  1‏
919 ‎‡a  roleofinfectionpreventionconferencestobuildandmaintainknowledgesharingnetworksalongitudinalevaluation‏ ‎‡A  The role of infection prevention conferences to build and maintain knowledge-sharing networks: a longitudinal evaluation‏ ‎‡9  1‏
919 ‎‡a  roleofneutropeniaonoutcomesofcancerpatientswithcommunityacquiredpneumonia‏ ‎‡A  The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  upperrespiratorytractmicrobiomeofhospitalisedpatientswithcommunityacquiredpneumoniaofunknownaetiologyapilotstudy‏ ‎‡A  The upper respiratory tract microbiome of hospitalised patients with community-acquired pneumonia of unknown aetiology: a pilot study‏ ‎‡9  1‏
919 ‎‡a  hivinfectiondoesnotinfluenceclinicaloutcomesinhospitalizedpatientswithbacterialcommunityacquiredpneumoniaresultsfromthecapointernationalcohortstudy‏ ‎‡A  HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study.‏ ‎‡9  1‏
919 ‎‡a  higherclinicalsuccessinpatientswithventilatorassociatedpneumoniaduetomethicillinresistantstaphylococcusaureustreatedwithlinezolidcomparedwithvancomycinresultsfromtheimpacthapstudy‏ ‎‡A  Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study‏ ‎‡9  1‏
919 ‎‡a  useofheteroduplexanalysisofpolymerasechainreactionproductstosupportthepossibletransmissionoflegionellapneumophilafromamalfunctioningautomobileairconditioner‏ ‎‡A  The use of heteroduplex analysis of polymerase chain reaction products to support the possible transmission of Legionella pneumophila from a malfunctioning automobile air conditioner‏ ‎‡9  1‏
919 ‎‡a  guidelinesforthemanagementofadultswithcommunityacquiredpneumoniadiagnosisassessmentofseverityantimicrobialtherapyandprevention‏ ‎‡A  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention‏ ‎‡9  1‏
919 ‎‡a  guidelinesforempiricantimicrobialprescribingincommunityacquiredpneumonia‏ ‎‡A  Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  useoflargedatabasestostudypneumoniawhatistheirvalue‏ ‎‡A  The use of large databases to study pneumonia: what is their value?‏ ‎‡9  1‏
919 ‎‡a  valueofreadytousedisinfectantwipescomplianceemployeetimeandcosts‏ ‎‡A  The value of ready-to-use disinfectant wipes: compliance, employee time, and costs‏ ‎‡9  1‏
919 ‎‡a  guidelinesforcommunityacquiredpneumoniawithindiseasemanagementprograms‏ ‎‡A  Guidelines for Community-Acquired Pneumonia Within Disease Management Programs‏ ‎‡9  1‏
919 ‎‡a  thrombocytopeniaandthrombocytosisattimeofhospitalizationpredictmortalityinpatientswithcommunityacquiredpneumonia‏ ‎‡A  Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  thrombocytosisinpatientswithseverecommunityacquiredpneumoniaresponse‏ ‎‡A  Thrombocytosis in Patients With Severe Community-Acquired Pneumonia: Response‏ ‎‡9  1‏
919 ‎‡a  tissuemicroarraytmaanalysisofnormalandpersistentchlamydophilapneumoniaeinfection‏ ‎‡A  Tissue MicroArray (TMA) analysis of normal and persistent Chlamydophila pneumoniae infection‏ ‎‡9  1‏
919 ‎‡a  guidelinesforcommunityacquiredpneumoniaintheusandcanadaapracticalapproachtoantibioticselection‏ ‎‡A  Guidelines for community-acquired pneumonia in the US and Canada: a practical approach to antibiotic selection‏ ‎‡9  1‏
919 ‎‡a  googlingyourhandhygienedatausinggoogleformsgooglesheetsandrtocollectandautomateanalysisofhandhygienecompliancemonitoring‏ ‎‡A  Googling your hand hygiene data: Using Google Forms, Google Sheets, and R to collect and automate analysis of hand hygiene compliance monitoring‏ ‎‡9  1‏
919 ‎‡a  treatmentofhospitalacquiredpneumoniaauthorsreply‏ ‎‡A  Treatment of hospital-acquired pneumonia – Authors' Reply‏ ‎‡9  1‏
919 ‎‡a  globalchangesintheepidemiologyofcommunityacquiredpneumonia‏ ‎‡A  Global changes in the epidemiology of community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  futureresearchdirectionsinpneumonianhlbiworkinggroupreport‏ ‎‡A  Future research directions in pneumonia: NHLBI working group report‏ ‎‡9  1‏
919 ‎‡a  evidenceforpersistentchlamydiapneumoniaeinfectionofhumancoronaryatheromas‏ ‎‡A  Evidence for persistent Chlamydia pneumoniae infection of human coronary atheromas‏ ‎‡9  1‏
919 ‎‡a  evaluationoftheknowledgesharingsocialnetworkofhospitalbasedinfectionpreventionistsinkentucky‏ ‎‡A  Evaluation of the knowledge-sharing social network of hospital-based infection preventionists in Kentucky‏ ‎‡9  1‏
919 ‎‡a  evaluationoftheeffectivenessofimprovedhydrogenperoxideintheoperatingroom‏ ‎‡A  Evaluation of the effectiveness of improved hydrogen peroxide in the operating room‏ ‎‡9  1‏
919 ‎‡a  evaluatingmentalhealthincubanrefugeestheroleoftherefugeehealthscreener15‏ ‎‡A  Evaluating Mental Health in Cuban Refugees: The Role of the Refugee Health Screener-15‏ ‎‡9  1‏
919 ‎‡a  establishingahospitalprogramtoimproveantimicrobialusecontrolbacterialresistanceandcontainhealthcarecoststheuniversityoflouisvilleexperience‏ ‎‡A  Establishing a hospital program to improve antimicrobial use, control bacterial resistance and contain healthcare costs: the University of Louisville experience.‏ ‎‡9  1‏
919 ‎‡a  endothelialadhesionmoleculesandmultipleorganfailureinpatientswithseveresepsis‏ ‎‡A  Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis.‏ ‎‡9  1‏
919 ‎‡a  empirictherapydirectedagainstmrsainpatientsadmittedtotheintensivecareunitdoesnotimproveoutcomesincommunityacquiredpneumonia‏ ‎‡A  Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia.‏ ‎‡9  1‏
919 ‎‡a  emergenceofmethicillinresistantstaphylococcusaureususa300genotypeasamajorcauseoflateonsetnosocomialpneumoniainintensivecarepatientsintheusa‏ ‎‡A  Emergence of methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of late-onset nosocomial pneumonia in intensive care patients in the USA.‏ ‎‡9  1‏
919 ‎‡a  efficacyofanovelskinantisepticagainstcarbapenemresistantenterobacteriaceae‏ ‎‡A  Efficacy of a novel skin antiseptic against carbapenem-resistant Enterobacteriaceae‏ ‎‡9  1‏
919 ‎‡a  effectsoffluoroquinolonesonthemigrationofhumanphagocytesthroughchlamydiapneumoniaeinfectedandtumornecrosisfactoralphastimulatedendothelialcells‏ ‎‡A  Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells‏ ‎‡9  1‏
919 ‎‡a  effectivenessof13valentpneumococcalconjugatevaccineagainsthospitalizationforcommunityacquiredpneumoniainolderusadultsatestnegativedesign‏ ‎‡A  Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.‏ ‎‡9  1‏
919 ‎‡a  effectofmacrolideantibioticsonhumanendothelialcellsactivatedbychlamydiapneumoniaeinfectionandtumornecrosisfactoralpha‏ ‎‡A  Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha‏ ‎‡9  1‏
919 ‎‡a  earlyswitchfromintravenoustooralantibioticsandearlyhospitaldischarge‏ ‎‡A  Early Switch From Intravenous to Oral Antibiotics and Early Hospital Discharge‏ ‎‡9  1‏
919 ‎‡a  earlyclinicalresponseincommunityacquiredbacterialpneumoniafromclinicalendpointtoclinicalpractice‏ ‎‡A  Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice‏ ‎‡9  1‏
919 ‎‡a  earlyadministrationofthe1antimicrobialsshouldbeconsideredamarkerofoptimalcareofpatientswithcommunityacquiredpneumoniaratherthanapredictorofoutcomes‏ ‎‡A  Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes‏ ‎‡9  1‏
919 ‎‡a  durationofantibiotictherapyinhospitalisedpatientswithcommunityacquiredpneumonia‏ ‎‡A  Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia.‏ ‎‡9  1‏
919 ‎‡a  disinfectantspraysversuswipesapplicationsinbehavioralhealth‏ ‎‡A  Disinfectant sprays versus wipes: Applications in behavioral health‏ ‎‡9  1‏
919 ‎‡a  diagnosticsensitivityandspecificityoftheradionuclideindiumlabeledleukocytescan‏ ‎‡A  Diagnostic sensitivity and specificity of the radionuclide (indium)-labeled leukocyte scan‏ ‎‡9  1‏
919 ‎‡a  developmentandimplementationofaperformanceimprovementprojectinadultintensivecareunitsoverviewoftheimprovingmedicinethroughpathwayassessmentofcriticaltherapyinhospitalacquiredpneumoniaimpacthapstudy‏ ‎‡A  Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study‏ ‎‡9  1‏
919 ‎‡a  decreaseinlongtermsurvivalforhospitalizedpatientswithcommunityacquiredpneumonia‏ ‎‡A  Decrease in long-term survival for hospitalized patients with community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  escalationtherapyamongbacteraemicpatientswithcommunityacquiredpneumonia‏ ‎‡A  De-escalation therapy among bacteraemic patients with community-acquired pneumonia.‏ ‎‡9  1‏
919 ‎‡a  cytokinesandneutrophilsresponsesininfluenzapneumonia‏ ‎‡A  Cytokines and neutrophils responses in influenza pneumonia.‏ ‎‡9  1‏
919 ‎‡a  criteriaforclinicalstabilityinhospitalisedpatientswithcommunityacquiredpneumonia‏ ‎‡A  Criteria for clinical stability in hospitalised patients with community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  costeffectivenessofadherencetoidsaatsguidelinesinelderlypatientshospitalizedforcommunityaquiredpneumonia‏ ‎‡A  Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia‏ ‎‡9  1‏
919 ‎‡a  controllingmultipledrugresistantorganismsatthehospitallevel‏ ‎‡A  Controlling multiple-drug-resistant organisms at the hospital level‏ ‎‡9  1‏
919 ‎‡a  contrastinginflammatoryresponsesinsevereandnonseverecommunityacquiredpneumonia‏ ‎‡A  Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia‏ ‎‡9  1‏
919 ‎‡a  computedtomographymeasurementsofparapneumoniceffusionindicativeofthoracentesis‏ ‎‡A  Computed tomography measurements of parapneumonic effusion indicative of thoracentesis.‏ ‎‡9  1‏
919 ‎‡a  comparingposteroanteriorwithlateralandanteroposteriorchestradiographyintheinitialdetectionofparapneumoniceffusions‏ ‎‡A  Comparing posteroanterior with lateral and anteroposterior chest radiography in the initial detection of parapneumonic effusions.‏ ‎‡9  1‏
919 ‎‡a  comparativestudyofthebactericidalactivityofampicillinsulbactamanderythromycinagainstintracellularlegionellapneumophila‏ ‎‡A  Comparative study of the bactericidal activity of ampicillin/sulbactam and erythromycin against intracellular Legionella pneumophila.‏ ‎‡9  1‏
919 ‎‡a  communityacquiredpneumoniaintheelderlyreply‏ ‎‡A  Community-Acquired Pneumonia in the Elderly Reply‏ ‎‡9  1‏
919 ‎‡a  communityacquiredpneumoniainadults‏ ‎‡A  Community-acquired pneumonia in adults‏ ‎‡9  1‏
919 ‎‡a  combinationantibiotictherapyandsynergyinhapandvap‏ ‎‡A  Combination antibiotic therapy and synergy in HAP and VAP‏ ‎‡9  1‏
919 ‎‡a  collaborationwithclinicalandtranslationalsciencestoimprovepsychiatrytraininginresearch‏ ‎‡A  Collaboration with clinical and translational sciences to improve psychiatry training in research‏ ‎‡9  1‏
919 ‎‡a  tuberculosisisalwaysapossibilityevenintheintensivecareunit‏ ‎‡A  Tuberculosis is always a possibility (even in the intensive care unit).‏ ‎‡9  1‏
919 ‎‡a  clinicalstabilityandswitchtherapyinhospitalisedpatientswithcommunityacquiredpneumoniaarewethereyet‏ ‎‡A  Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet?‏ ‎‡9  1‏
919 ‎‡a  clinicalscoringtoolswhichisbesttopredictclinicalresponseandlongtermoutcomes‏ ‎‡A  Clinical scoring tools: which is best to predict clinical response and long-term outcomes?‏ ‎‡9  1‏
919 ‎‡a  clinicaloutcomesofhivinfectedpatientshospitalizedwithbacterialcommunityacquiredpneumonia‏ ‎‡A  Clinical outcomes of HIV-infected patients hospitalized with bacterial community-acquired pneumonia.‏ ‎‡9  1‏
919 ‎‡a  clinicalandeconomicburdenofpneumoniaamongadultsinlatinamerica‏ ‎‡A  Clinical and economic burden of pneumonia among adults in Latin America‏ ‎‡9  1‏
919 ‎‡a  characterizationofchlamydiapneumoniaepersistenceinhep2cellstreatedwithgammainterferon‏ ‎‡A  Characterization of Chlamydia pneumoniae persistence in HEp-2 cells treated with gamma interferon.‏ ‎‡9  1‏
919 ‎‡a  characteristicsofhospitalisedpatientswith2009h1n1influenzainchile‏ ‎‡A  Characteristics of hospitalised patients with 2009 H1N1 influenza in Chile.‏ ‎‡9  1‏
919 ‎‡a  understandingtherolesofcytokinesandneutrophilactivityandneutrophilapoptosisintheprotectiveversusdeleteriousinflammatoryresponseinpneumonia‏ ‎‡A  Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia‏ ‎‡9  1‏
919 ‎‡a  characteristicsassociatedwithcliniciandiagnosisofaspirationpneumoniaadescriptivestudyofafflictedpatientsandtheiroutcomes‏ ‎‡A  Characteristics associated with clinician diagnosis of aspiration pneumonia: a descriptive study of afflicted patients and their outcomes‏ ‎‡9  1‏
919 ‎‡a  changingneedsofcommunityacquiredpneumonia‏ ‎‡A  Changing needs of community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  understandingwhylowriskpatientsacceptvaccinesasociobehavioralapproach‏ ‎‡A  Understanding why low-risk patients accept vaccines: a socio-behavioral approach‏ ‎‡9  1‏
919 ‎‡a  usingclusteranalysisofcytokinestoidentifypatternsofinflammationinhospitalizedpatientswithcommunityacquiredpneumoniaapilotstudy‏ ‎‡A  Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study‏ ‎‡9  1‏
919 ‎‡a  cd4+cellcountsandhivrnalevelsdonotpredictoutcomesofcommunityacquiredpneumoniainhospitalizedhivinfectedpatients‏ ‎‡A  CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients‏ ‎‡9  1‏
919 ‎‡a  cardiacdiseasescomplicatingcommunityacquiredpneumonia‏ ‎‡A  Cardiac diseases complicating community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  bacteremicpneumococcalpneumoniaclinicaloutcomesandpreliminaryresultsofinflammatoryresponse‏ ‎‡A  Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response.‏ ‎‡9  1‏
919 ‎‡a  associationbetweentimetoclinicalstabilityandoutcomesafterdischargeinhospitalizedpatientswithcommunityacquiredpneumonia‏ ‎‡A  Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  antigensofpersistentchlamydiapneumoniaewithincoronaryatheromafrompatientsundergoinghearttransplantation‏ ‎‡A  Antigens of persistent Chlamydia pneumoniae within coronary atheroma from patients undergoing heart transplantation‏ ‎‡9  1‏
919 ‎‡a  antibioticstreamliningdevelopmentandjustificationofanantibioticstreamliningprogram‏ ‎‡A  Antibiotic streamlining: development and justification of an antibiotic streamlining program‏ ‎‡9  1‏
919 ‎‡a  analysisofresistancecrossresistanceandantimicrobialcombinationsforpseudomonasaeruginosaisolatesfrom1997to‏ ‎‡A  Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009‏ ‎‡9  1‏
919 ‎‡a  analysisofpathogenandhostfactorsrelatedtoclinicaloutcomesinpatientswithhospitalacquiredpneumoniaduetomethicillinresistantstaphylococcusaureus‏ ‎‡A  Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus‏ ‎‡9  1‏
919 ‎‡a  advancesinantibioticuseswitchtherapy‏ ‎‡A  Advances in antibiotic use: Switch therapy‏ ‎‡9  1‏
919 ‎‡a  adultshospitalizedwithpneumoniaintheunitedstatesincidenceepidemiologyandmortality‏ ‎‡A  Adults Hospitalized with Pneumonia in the United States: Incidence, Epidemiology and Mortality‏ ‎‡9  2‏
919 ‎‡a  adherencewithnationalguidelinesinhospitalizedpatientswithcommunityacquiredpneumoniaresultsfromthecapostudyinvenezuela‏ ‎‡A  Adherence with national guidelines in hospitalized patients with community-acquired pneumonia: results from the CAPO study in Venezuela‏ ‎‡9  1‏
919 ‎‡a  addressingthechallengesofrefugeehealthexperiencesfromtheuniversityoflouisvilleinterprofessionalrefugeeimmunizationclinic‏ ‎‡A  Addressing the challenges of refugee health: Experiences from the University of Louisville interprofessional refugee immunization clinic‏ ‎‡9  1‏
919 ‎‡a  acutemyocardialinfarctionversusothercardiovasculareventsincommunityacquiredpneumonia‏ ‎‡A  Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  acutemyocardialinfarctioninhospitalizedpatientswithcommunityacquiredpneumonia‏ ‎‡A  Acute myocardial infarction in hospitalized patients with community-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  absenceofgenderbaseddifferencesinoutcomeofpatientswithhospitalacquiredpneumonia‏ ‎‡A  Absence of gender-based differences in outcome of patients with hospital-acquired pneumonia‏ ‎‡9  1‏
919 ‎‡a  usingsteroidsinpatientswithcommunityacquiredpneumoniaattheuniversityoflouisvillehospitalwhowhatandwhen‏ ‎‡A  Using Steroids in Patients with Community-Acquired Pneumonia at the University of Louisville Hospital: Who, What, and When‏ ‎‡9  1‏
919 ‎‡a  worldwideperspectiveofnursinghomeacquiredpneumoniacomparedwithcommunityacquiredpneumonia‏ ‎‡A  A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia.‏ ‎‡9  1‏
919 ‎‡a  ventilatorassociatedpneumoniaincriticallyillstrokepatientsfrequencyriskfactorsandoutcomes‏ ‎‡A  Ventilator-associated pneumonia in critically ill stroke patients: Frequency, risk factors, and outcomes‏ ‎‡9  1‏
919 ‎‡a  worldwideperspectiveofatypicalpathogensincommunityacquiredpneumonia‏ ‎‡A  A worldwide perspective of atypical pathogens in community-acquired pneumonia.‏ ‎‡9  1‏
919 ‎‡a  singlegenotypeofacinetobacterbaumanniiexpressesmultipleantibioticsusceptibilityphenotypes‏ ‎‡A  A single genotype of Acinetobacter baumannii expresses multiple antibiotic susceptibility phenotypes‏ ‎‡9  1‏
919 ‎‡a  randomizedstudyevaluatingtheeffectivenessofoseltamivirinitiatedatthetimeofhospitaladmissioninadultshospitalizedwithinfluenzaassociatedlowerrespiratorytractinfections‏ ‎‡A  A Randomized Study Evaluating the Effectiveness of Oseltamivir Initiated at the Time of Hospital Admission in Adults Hospitalized With Influenza-Associated Lower Respiratory Tract Infections.‏ ‎‡9  1‏
919 ‎‡a  processforanalysisofsentineleventsduetohealthcareassociatedinfection‏ ‎‡A  A process for analysis of sentinel events due to health care-associated infection‏ ‎‡9  1‏
919 ‎‡a  viralinfectionincommunityacquiredpneumoniaasystematicreviewandmetaanalysis‏ ‎‡A  Viral infection in community-acquired pneumonia: a systematic review and meta-analysis‏ ‎‡9  1‏
919 ‎‡a  visualgridsformanagingdatacompletenessinclinicalresearchdatasets‏ ‎‡A  Visual grids for managing data completeness in clinical research datasets‏ ‎‡9  1‏
919 ‎‡a  vitamin500receptorhomozygotemutantttandbbareassociatedwithsusceptibilitytopulmonarytuberculosisintheiranianpopulation‏ ‎‡A  Vitamin D receptor homozygote mutant tt and bb are associated with susceptibility to pulmonary tuberculosis in the Iranian population.‏ ‎‡9  1‏
919 ‎‡a  whatistheassociationofcardiovasculareventswithclinicalfailureinpatientswithcommunityacquiredpneumonia‏ ‎‡A  What is the association of cardiovascular events with clinical failure in patients with community-acquired pneumonia?‏ ‎‡9  1‏
919 ‎‡a  whatisthebesttherapeuticapproachtomethicillinresistantstaphylococcusaureuspneumonia‏ ‎‡A  What is the best therapeutic approach to methicillin-resistant Staphylococcus aureus pneumonia?‏ ‎‡9  1‏
919 ‎‡a  worldwideperspectiveofthequalityofcareprovidedtohospitalizedpatientswithcommunityacquiredpneumoniaresultsfromthecapointernationalcohortstudy‏ ‎‡A  Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study‏ ‎‡9  1‏
919 ‎‡a  شروعبهکاربادادههایبهداشتیدستشمابااستفادهازفرمهایgooglegooglesheetsوrبرایجمعاوریوخودکارکردنتجزیهوتحلیلنظارتبررعایتبهداشتدست‏ ‎‡A  شروع به کار با داده های بهداشتی دست شما: با استفاده از فرم های Google ، Google Sheets و R برای جمع آوری و خودکار کردن تجزیه و تحلیل نظارت بر رعایت بهداشت دست.‏ ‎‡9  1‏
919 ‎‡a  improvingoutcomesinelderlypatientswithcommunityacquiredpneumoniabyadheringtonationalguidelinescommunityacquiredpneumoniaorganizationinternationalcohortstudyresults‏ ‎‡A  Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.‏ ‎‡9  1‏
919 ‎‡a  macrolideuseandneutrophilfunctioncytokinelevelsinhospitalizedpatientswithcommunityacquiredpneumoniaapilotstudy‏ ‎‡A  Macrolide Use and Neutrophil Function/Cytokine Levels in Hospitalized Patients with Community-Acquired Pneumonia: A Pilot Study‏ ‎‡9  1‏
919 ‎‡a  lungcytokinesandsystemicinflammationinpatientswithcopd‏ ‎‡A  Lung Cytokines and Systemic Inflammation in Patients with COPD‏ ‎‡9  1‏
943 ‎‡a  200x‏ ‎‡A  2008‏ ‎‡9  2‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  SUDOC|153339942‏
996 ‎‡2  LC|n 92093993‏
996 ‎‡2  BNF|16978526‏
996 ‎‡2  LC|ns2017003287‏
996 ‎‡2  RERO|A024532398‏
996 ‎‡2  LC|n 2006055181‏
996 ‎‡2  DNB|1057145483‏
996 ‎‡2  LC|no2005111583‏
996 ‎‡2  ARBABN|000065546‏
996 ‎‡2  DNB|1033199109‏
996 ‎‡2  LC|no 96051769‏
996 ‎‡2  LC|no2003043124‏
996 ‎‡2  DNB|1300938609‏
996 ‎‡2  LC|n 2008029769‏
996 ‎‡2  BNC|981058617959206706‏
996 ‎‡2  LC|nb2009002561‏
996 ‎‡2  LIH|LNB:V-277451;=BM‏
996 ‎‡2  ISNI|0000000083320480‏
996 ‎‡2  BNCHL|10000000000000000145903‏
996 ‎‡2  LC|no2022146066‏
996 ‎‡2  ISNI|0000000094897971‏
996 ‎‡2  BNCHL|10000000000000000008050‏
996 ‎‡2  LC|n 97097014‏
996 ‎‡2  ISNI|0000000431259162‏
996 ‎‡2  BNE|XX1386522‏
996 ‎‡2  LC|n 98065234‏
996 ‎‡2  LC|no 00035602‏
996 ‎‡2  ISNI|0000000030912271‏
996 ‎‡2  ISNI|0000000039455724‏
996 ‎‡2  DNB|105711796X‏
996 ‎‡2  ISNI|000000003660355X‏
996 ‎‡2  ISNI|0000000447385956‏
996 ‎‡2  ISNI|0000000503903720‏
996 ‎‡2  DNB|134596269‏
996 ‎‡2  LC|n 2010049472‏
996 ‎‡2  DNB|124040526X‏
996 ‎‡2  NKC|jo20221155648‏
996 ‎‡2  LC|n 2001098581‏
996 ‎‡2  LC|n 96085276‏
996 ‎‡2  LC|no2021061656‏
996 ‎‡2  LC|n 2014061055‏
996 ‎‡2  ISNI|0000000038500386‏
996 ‎‡2  ISNI|0000000024880699‏
996 ‎‡2  BNE|XX938466‏
996 ‎‡2  BNE|XX1165987‏
996 ‎‡2  ISNI|0000000437197812‏
996 ‎‡2  ARBABN|000049953‏
996 ‎‡2  LC|no2012041355‏
996 ‎‡2  LC|no2018132603‏
996 ‎‡2  SUDOC|20068440X‏
996 ‎‡2  LC|n 88629299‏
996 ‎‡2  ISNI|0000000094357908‏
996 ‎‡2  ISNI|0000000108860521‏
996 ‎‡2  W2Z|1579001846864‏
996 ‎‡2  LC|no2015031217‏
996 ‎‡2  LC|no2023007786‏
996 ‎‡2  BNF|12415918‏
996 ‎‡2  BNF|17932349‏
996 ‎‡2  LC|no2010076419‏
996 ‎‡2  DNB|1211038297‏
996 ‎‡2  SUDOC|182392872‏
996 ‎‡2  LC|no2010144512‏
996 ‎‡2  ISNI|0000000081039572‏
996 ‎‡2  BNCHL|10000000000000000125412‏
996 ‎‡2  ISNI|0000000384299769‏
996 ‎‡2  LC|no2002046627‏
996 ‎‡2  DNB|1032676361‏
996 ‎‡2  ISNI|0000000042330332‏
996 ‎‡2  DNB|1056249668‏
996 ‎‡2  LC|n 85052245‏
996 ‎‡2  BIBSYS|1579001846864‏
996 ‎‡2  SUDOC|03327679X‏
996 ‎‡2  LC|no2023035345‏
996 ‎‡2  ISNI|0000000052113753‏
996 ‎‡2  BNCHL|10000000000000000092138‏
996 ‎‡2  ISNI|0000000079181713‏
996 ‎‡2  DNB|136489303‏
996 ‎‡2  LC|n 79102745‏
996 ‎‡2  DNB|1239189087‏
996 ‎‡2  BNC|981058509300406706‏
996 ‎‡2  ISNI|0000000088256078‏
996 ‎‡2  BNCHL|10000000000000000200562‏
996 ‎‡2  BNE|XX4765824‏
996 ‎‡2  LC|no 95015863‏
996 ‎‡2  RERO|A011143716‏
996 ‎‡2  BNCHL|10000000000000000291261‏
996 ‎‡2  LC|n 91026187‏
996 ‎‡2  ISNI|0000000031011133‏
996 ‎‡2  RERO|A026663638‏
996 ‎‡2  ICCU|BVEV186691‏
996 ‎‡2  SUDOC|188739734‏
996 ‎‡2  DE633|pe41022256‏
996 ‎‡2  DNB|1137563869‏
996 ‎‡2  RERO|A009199032‏
996 ‎‡2  CAOONL|ncf11880529‏
996 ‎‡2  NTA|133701123‏
996 ‎‡2  SUDOC|257131809‏
996 ‎‡2  ISNI|0000000040641815‏
996 ‎‡2  BNF|17973472‏
996 ‎‡2  ISNI|0000000029992198‏
996 ‎‡2  LC|n 94120649‏
996 ‎‡2  ISNI|0000000032529161‏
996 ‎‡2  NTA|412932806‏
996 ‎‡2  BNCHL|10000000000000000197394‏
996 ‎‡2  ISNI|0000000059418031‏
996 ‎‡2  LC|no2021098001‏
996 ‎‡2  LC|no2010164859‏
996 ‎‡2  LC|n 87113451‏
996 ‎‡2  ISNI|0000000043195451‏
996 ‎‡2  LC|no2010051692‏
996 ‎‡2  SUDOC|271282584‏
996 ‎‡2  BIBSYS|8068826‏
996 ‎‡2  RERO|A025365992‏
996 ‎‡2  NTA|133289532‏
996 ‎‡2  ISNI|0000000139328490‏
996 ‎‡2  NUKAT|n 2023120686‏
996 ‎‡2  BNE|XX1636984‏
996 ‎‡2  SUDOC|13421367X‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏
998 ‎‡a  Ramirez, Julio A.‏ ‎‡c  (Professor of Medicine)‏ ‎‡2  LC|n 2002136142‏ ‎‡3  suggested‏ ‎‡3  title: (0.89, 'communityacquiredpneumonia', 'communityacquiredpneumoniainadults')‏
998 ‎‡a  Ramirez‏ ‎‡b  Julio A.‏ ‎‡2  BNF|16978526‏ ‎‡3  viafid‏
998 ‎‡a  Ramirez, Julio‏ ‎‡2  PLWABN|9810569926005606‏ ‎‡3  exact title: (1.00, 'kawasakilikediseasekldinanadultwithcongenitalhivinfection', 'kawasakilikediseasekldinanadultwithcongenitalhivinfection')‏